| 3.24 -0.26 (-7.43%) | 11-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.11 | 1-year : | 4.8 |
| Resists | First : | 3.51 | Second : | 4.11 |
| Pivot price | 3.05  |
|||
| Supports | First : | 2.54 | Second : | 1.94 |
| MAs | MA(5) : | 3.29 |
MA(20) : | 2.89 |
| MA(100) : | 2.46 |
MA(250) : | 2.33 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 83.7 |
D(3) : | 83.9 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 5.96 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INDP ] has closed below upper band by 35.9%. Bollinger Bands are 32.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.4 - 3.42 | 3.42 - 3.44 |
| Low: | 3.17 - 3.19 | 3.19 - 3.2 |
| Close: | 3.21 - 3.24 | 3.24 - 3.26 |
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Sat, 31 Oct 2026
Indaptus Therapeutics (INDP) Slides 7.49% to $3.09 as Shares Test Lower Support - MESA MA - https://www.siam.in/
Fri, 30 Oct 2026
Indaptus Therapeutics (INDP) Latest Announcement & Press Release - Moomoo
Fri, 23 Oct 2026
Indaptus Therapeutics, Inc. Estimates – NASDAQ:INDP - TradingView
Thu, 22 Oct 2026
The CEO’s ownership share fell without a sale at Indaptus Therapeutics (INDP). - Stock Titan
Wed, 21 Oct 2026
Indaptus Therapeutics Inc (INDP-Q) Stock Price and News - The Globe and Mail
Tue, 20 Oct 2026
Indaptus Therapeutics completes $24 million private placement of common stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 133 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 70.6 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 822 (K) |
| Shares Short P.Month | 212 (K) |
| EPS | -6.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -98.1 % |
| Return on Equity (ttm) | -318.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.53 |
| PEG Ratio | 0 |
| Price to Book value | 36 |
| Price to Sales | 0 |
| Price to Cash Flow | -29.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|